{
  "items": "50",
  "sentiment_score_definition": "x <= -0.35: Bearish; -0.35 < x <= -0.15: Somewhat-Bearish; -0.15 < x < 0.15: Neutral; 0.15 <= x < 0.35: Somewhat_Bullish; x >= 0.35: Bullish",
  "relevance_score_definition": "0 < x <= 1, with a higher score indicating higher relevance.",
  "feed": [
    {
      "title": "New to The Street's Prestigious Client NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Receives Notification of US Food and Drug Administration Approval of Suitability Petition for NRx's Proposed Strength of Preservative-Free Ketamine",
      "url": "https://www.sentinel-standard.com/press-release/story/6293/new-to-the-streets-prestigious-client-nrx-pharmaceuticals-inc-nasdaqnrxp-receives-notification-of-us-food-and-drug-administration-approval-of-suitability-petition-for-nrxs-proposed-strength-of-preserv/",
      "time_published": "20251228T110905",
      "authors": [
        "New To The Street"
      ],
      "summary": "NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) announced that the FDA has granted a Suitability Petition for its proposed single-patient, preservative-free ketamine product (KETAFREE\u2122). This approval allows NRx to re-file its Abbreviated New Drug Application (ANDA) for KETAFREE\u2122, which aims to replace multi-dose ketamine vials containing toxic preservatives and aligns with FDA objectives for safe, re-shored sterile drug manufacturing. The company believes KETAFREE\u2122 will be a successful product in the estimated $750 million ketamine market, alongside its non-generic formulation NRX-100 for suicidal depression and PTSD.",
      "banner_image": "https://app.accessnewswire.com/img.ashx?id=1077512",
      "source": "Sentinel-Standard",
      "category_within_source": "General",
      "source_domain": "Sentinel-Standard",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "1.000000"
        }
      ],
      "overall_sentiment_score": 0.440488,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "NRXP",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.420090",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "NRx Pharmaceuticals (NASDAQ: NRXP) Eliminates Balance Sheet Debt Through Anson Equity Conversion",
      "url": "https://www.theglobeandmail.com/investing/markets/stocks/NRXP-Q/pressreleases/36695804/nrx-pharmaceuticals-nasdaq-nrxp-eliminates-balance-sheet-debt-through-anson-equity-conversion/",
      "time_published": "20251219T130831",
      "authors": [
        "NULL"
      ],
      "summary": "NRx Pharmaceuticals (NASDAQ: NRXP) has eliminated its remaining $5.4 million balance sheet debt to Anson Funds LLC through an equity conversion, fully retiring the original $16.2 million loan. This move positions the clinical-stage biopharmaceutical company to be debt-free by the end of 2025, strengthening its capital structure for anticipated drug approvals and clinic expansions. Chairman and CEO Dr. Jonathan Javitt thanked Anson for their support and highlighted progress toward potential 2026 approvals for treatments addressing suicidal depression and PTSD.",
      "banner_image": "NULL",
      "source": "The Globe and Mail",
      "category_within_source": "General",
      "source_domain": "The Globe and Mail",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.913254"
        },
        {
          "topic": "earnings",
          "relevance_score": "0.734183"
        },
        {
          "topic": "finance",
          "relevance_score": "0.648794"
        }
      ],
      "overall_sentiment_score": 0.479421,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "NRXP",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.493951",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "NRx Pharmaceuticals (NASDAQ: NRXP) Eliminates Balance Sheet Debt Through Anson Equity Conversion",
      "url": "https://www.digitaljournal.com/pr/news/investorbrandnetwork/nrx-pharmaceuticals-nasdaq-nrxp-eliminates-1811169548.html",
      "time_published": "20251219T001135",
      "authors": [
        "InvestorBrandNetwork"
      ],
      "summary": "NRx Pharmaceuticals announced it has eliminated $5.4 million in balance sheet debt owed to Anson Funds LLC through an equity conversion, fully retiring the original $16.2 million loan. This transaction positions the company to be debt-free by the end of 2025, supporting future drug approvals and clinical expansions. Chairman and CEO Dr. Jonathan Javitt highlighted progress towards potential 2026 approvals for treatments addressing suicidal depression and PTSD.",
      "banner_image": "https://www.digitaljournal.com/wp-content/uploads/2021/01/Digital-Journal-Logosm@2x.png",
      "source": "Digital Journal",
      "category_within_source": "General",
      "source_domain": "Digital Journal",
      "topics": [
        {
          "topic": "finance",
          "relevance_score": "0.818049"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "1.000000"
        }
      ],
      "overall_sentiment_score": 0.008893,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "NRXP",
          "relevance_score": "0.301153",
          "ticker_sentiment_score": "0.013120",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "NRx Pharmaceuticals Announces Elimination of All Balance Sheet Debt Following Equity Conversion",
      "url": "https://www.citybiz.co/article/786176/nrx-pharmaceuticals-announces-elimination-of-all-balance-sheet-debt-following-equity-conversion/?abkw=citybiznewyork",
      "time_published": "20251218T141135",
      "authors": [
        "NULL"
      ],
      "summary": "NRx Pharmaceuticals, Inc. announced the elimination of its entire $5.4 million balance sheet debt to Anson Funds, LLC through an equity conversion of common stock. This strategic move positions the company to end the 2025 calendar year debt-free, strengthening its capital structure for anticipated growth, drug approvals, and clinic expansions in the coming year, particularly for its central nervous system disorder therapeutics. Dr. Jonathan Javitt, CEO, thanked Anson Funds for their support in advancing their clinical programs for suicidal depression and PTSD.",
      "banner_image": "https://www.citybiz.co/wp-content/uploads/2024/05/nrx-pharmaceuticals.jpg",
      "source": "citybiz",
      "category_within_source": "General",
      "source_domain": "citybiz",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.924026"
        },
        {
          "topic": "earnings",
          "relevance_score": "0.913510"
        },
        {
          "topic": "finance",
          "relevance_score": "0.714862"
        }
      ],
      "overall_sentiment_score": 0.455804,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "NRXP",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.466300",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "NRx Pharmaceuticals (Nasdaq:NRXP) announces elimination of all balance sheet debt following equity conversion",
      "url": "https://www.globenewswire.com/news-release/2025/12/18/3207579/0/en/NRx-Pharmaceuticals-Nasdaq-NRXP-announces-elimination-of-all-balance-sheet-debt-following-equity-conversion.html",
      "time_published": "20251218T131135",
      "authors": [],
      "summary": "NRx Pharmaceuticals (Nasdaq: NRXP) announced the elimination of its remaining $5.4 million balance sheet debt through an equity conversion of common stock with Anson Funds. This strategic move positions the company for accelerated growth in 2026, anticipating drug approvals and clinic expansions. NRx Pharmaceuticals aims to end 2025 with a debt-free balance sheet to support its clinical-stage biopharmaceutical programs.",
      "banner_image": "https://ml.globenewswire.com/media/MTliNDExNWUtMTVmMy00YzM0LWJmNGEtYzRiMTk5ZTNiMTVkLTEwOTU2OTMtMjAyNS0xMi0xOC1lbg==/tiny/NRx-Pharmaceuticals-Inc.png",
      "source": "GlobeNewswire",
      "category_within_source": "General",
      "source_domain": "GlobeNewswire",
      "topics": [
        {
          "topic": "earnings",
          "relevance_score": "0.947655"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.834384"
        }
      ],
      "overall_sentiment_score": 0.86454,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "NRXP",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.867874",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "NRx Pharmaceuticals announces elimination of all balance sheet debt following equity conversion",
      "url": "https://investingnews.com/nrx-pharmaceuticals-announces-elimination-of-all-balance-sheet-debt-following-equity-conversion/",
      "time_published": "20251218T125846",
      "authors": [],
      "summary": "NRx Pharmaceuticals, Inc. announced the elimination of its remaining $5.4 million balance sheet debt through an equity conversion of common stock to Anson Funds, LLC, without additional warrants or adjustment provisions. This strategic move positions the company for accelerated growth in 2026, with anticipated drug approvals and clinic expansions. The company expects to end the 2025 calendar year with a debt-free balance sheet.",
      "banner_image": "https://investingnews.com/media-library/image.gif?id=29654767&width=1200&height=1200",
      "source": "Investing News Network",
      "category_within_source": "General",
      "source_domain": "Investing News Network",
      "topics": [
        {
          "topic": "earnings",
          "relevance_score": "0.931758"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.804939"
        },
        {
          "topic": "finance",
          "relevance_score": "0.714862"
        }
      ],
      "overall_sentiment_score": 0.41648,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "NRXP",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.423592",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "NRx Pharmaceuticals clears remaining $5.4 million debt",
      "url": "https://www.investing.com/news/company-news/nrx-pharmaceuticals-clears-remaining-54-million-debt-93CH-4414757",
      "time_published": "20251218T122746",
      "authors": [
        "Investing.com"
      ],
      "summary": "NRx Pharmaceuticals (NASDAQ:NRXP) has eliminated its remaining $5.4 million balance sheet debt to Anson Funds, LLC through an equity conversion, positioning the company for growth in 2026. Despite ongoing profitability challenges (EBITDA of -$15.2 million), the biopharmaceutical firm aims to end 2025 debt-free as it progresses with drug approvals and clinic expansions. The company is developing treatments for central nervous system disorders, including suicidal depression, and recently reported its first revenue of approximately $240,000 from its Hope Therapeutics clinic network.",
      "banner_image": "https://i-invdn-com.investing.com/news/news_pile_69x52._800x533_L_1419494209.jpg",
      "source": "Investing.com",
      "category_within_source": "General",
      "source_domain": "Investing.com",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.913477"
        },
        {
          "topic": "earnings",
          "relevance_score": "0.831955"
        }
      ],
      "overall_sentiment_score": 0.424134,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "NRXP",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.393463",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "NRx Pharmaceuticals Completes Repayment of $5.4 Million Debt, Positioning Company for Growth in 2026",
      "url": "https://www.quiverquant.com/news/NRx+Pharmaceuticals+Completes+Repayment+of+%245.4+Million+Debt%2C+Positioning+Company+for+Growth+in+2026",
      "time_published": "20251218T121700",
      "authors": [],
      "summary": "NRx Pharmaceuticals has repaid its remaining $5.4 million debt to Anson Funds through an equity conversion, aiming for a debt-free balance sheet by the end of 2025. This move is expected to position the company for accelerated growth in 2026, including potential drug approvals and clinic expansions. NRx Pharmaceuticals is focused on developing treatments for central nervous system disorders with several products in its pipeline that have received expedited regulatory review designations.",
      "banner_image": "https://www.quiverquant.com/images/nrxp_rect_new.png",
      "source": "Quiver Quantitative",
      "category_within_source": "General",
      "source_domain": "Quiver Quantitative",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.928802"
        },
        {
          "topic": "earnings",
          "relevance_score": "0.823841"
        },
        {
          "topic": "financial_markets",
          "relevance_score": "0.629186"
        }
      ],
      "overall_sentiment_score": 0.530018,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "NRXP",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.512112",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "Biotech wipes out final $5.4M debt as it pursues depression treatments",
      "url": "https://www.stocktitan.net/news/NRXP/n-rx-pharmaceuticals-nasdaq-nrxp-announces-elimination-of-all-vnzzfqoida6a.html",
      "time_published": "20251218T120946",
      "authors": [],
      "summary": "NRx Pharmaceuticals announced it has eliminated its remaining $5.4 million balance sheet debt by converting it into common stock with Anson Funds, anticipating a debt-free balance sheet by December 31, 2025. This move strengthens the company's capital structure for accelerated growth, potential drug approvals, and clinic expansions in 2026, particularly for its central nervous system disorder treatments. The stock reacted positively to this news, gaining 5.26%.",
      "banner_image": "https://ml.globenewswire.com/media/MTliNDExNWUtMTVmMy00YzM0LWJmNGEtYzRiMTk5ZTNiMTVkLTEwOTU2OTMtMjAyNS0xMi0xOC1lbg==/tiny/NRx-Pharmaceuticals-Inc.png",
      "source": "Stock Titan",
      "category_within_source": "General",
      "source_domain": "Stock Titan",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.940800"
        },
        {
          "topic": "earnings",
          "relevance_score": "0.834609"
        },
        {
          "topic": "financial_markets",
          "relevance_score": "0.702645"
        },
        {
          "topic": "finance",
          "relevance_score": "0.614050"
        }
      ],
      "overall_sentiment_score": 0.405898,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "NRXP",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.405675",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "NRx Pharmaceuticals (NASDAQ:NRXP) Given Buy Rating at HC Wainwright",
      "url": "https://www.marketbeat.com/instant-alerts/nrx-pharmaceuticals-nasdaqnrxp-given-buy-rating-at-hc-wainwright-2025-12-16/",
      "time_published": "20251216T133348",
      "authors": [
        "MarketBeat"
      ],
      "summary": "HC Wainwright has reiterated a \"Buy\" rating for NRx Pharmaceuticals (NASDAQ:NRXP), setting a price target of $40.00. The clinical-stage biopharmaceutical company, which develops novel therapeutics for CNS disorders, has a consensus \"Moderate Buy\" rating from analysts with an average price target of $36.50, despite recently missing quarterly EPS estimates and reporting low revenue.",
      "banner_image": "https://www.marketbeat.com/logos/nrx-pharmaceuticals-inc-logo-1200x675.png",
      "source": "MarketBeat",
      "category_within_source": "General",
      "source_domain": "MarketBeat",
      "topics": [
        {
          "topic": "earnings",
          "relevance_score": "0.913069"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.845005"
        },
        {
          "topic": "financial_markets",
          "relevance_score": "0.725110"
        }
      ],
      "overall_sentiment_score": 0.196383,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "NRXP",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.160929",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "NRx Eyes Faster Commercial Path as NRX-101 Moves Into TMS-Enhanced Depression Treatment",
      "url": "https://www.mychesco.com/a/news/regional/nrx-eyes-faster-commercial-path-as-nrx-101-moves-into-tms-enhanced-depression-treatment/",
      "time_published": "20251209T140922",
      "authors": [
        "Timothy Alexander"
      ],
      "summary": "NRx Pharmaceuticals (Nasdaq: NRXP) is expanding its NRX-101 development to include Transcranial Magnetic Stimulation (TMS) for major depression, aiming for a faster market path. This decision is driven by evidence that low-dose D-cycloserine, a component of NRX-101, significantly enhances TMS effects. The company anticipates a pivotal study involving 120 participants could be sufficient for registration, with discussions underway for a joint clinical trial with TMS device manufacturers.",
      "banner_image": "https://i0.wp.com/www.mychesco.com/wp-content/uploads/2022/11/NRx-Pharmaceuticals.jpg?resize=735%2C400&ssl=1",
      "source": "MyChesCo",
      "category_within_source": "General",
      "source_domain": "MyChesCo",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.933557"
        }
      ],
      "overall_sentiment_score": 0.46097,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "NRXP",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.452300",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "NRx\u2019s Preservative-Free Ketamine Reaches FDA Review as Company Targets 2026 Launch",
      "url": "https://www.mychesco.com/a/news/regional/nrxs-preservative-free-ketamine-reaches-fda-review-as-company-targets-2026-launch/",
      "time_published": "20251208T190922",
      "authors": [
        "Timothy Alexander"
      ],
      "summary": "NRx Pharmaceuticals has announced that its Abbreviated New Drug Application for KETAFREE, a preservative-free intravenous ketamine product, has been accepted for review by the U.S. FDA. The FDA has set a review deadline of July 29, 2026, and if approved, KETAFREE would be the first single-patient ketamine presentation without Benzethonium Chloride, potentially addressing a $750 million annual market. NRx is prepared to scale manufacturing for a potential 2026 launch.",
      "banner_image": "https://i0.wp.com/www.mychesco.com/wp-content/uploads/2022/11/NRx-Pharmaceuticals.jpg?resize=735%2C400&ssl=1",
      "source": "MyChesCo",
      "category_within_source": "General",
      "source_domain": "MyChesCo",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.904791"
        }
      ],
      "overall_sentiment_score": 0.420431,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "NRXP",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.405062",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "NRx Pharmaceuticals (NASDAQ: NRXP) and HOPE Therapeutics to Host Corporate Update Call",
      "url": "https://fox59.com/business/press-releases/globenewswire/9595001/nrx-pharmaceuticals-nasdaq-nrxp-and-hope-therapeutics-to-host-corporate-update-call",
      "time_published": "20251205T150935",
      "authors": [
        "NULL"
      ],
      "summary": "NRx Pharmaceuticals and its subsidiary HOPE Therapeutics will host a corporate update conference call on Tuesday, December 2, 2025, at 9:00 AM ET. The call will cover recent clinical, regulatory, and operational developments for both companies, focusing on their neuroplastic therapies for central nervous system disorders, including suicidal depression. The webcast will be available on the NRx Pharmaceuticals website.",
      "banner_image": "https://ml.globenewswire.com/media/d879f1ff-d5d7-48d7-9731-c881b469d873/small/nrx-logo-300dpi-png.png",
      "source": "Fox 59",
      "category_within_source": "General",
      "source_domain": "Fox 59",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.902147"
        },
        {
          "topic": "earnings",
          "relevance_score": "0.735769"
        }
      ],
      "overall_sentiment_score": 0.177345,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "NRXP",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.155835",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "NRx Pharmaceuticals to discuss new NRX-101 pipeline indication for augmentation of Transcranial Magnetic Stimulation",
      "url": "https://investingnews.com/nrx-pharmaceuticals-to-discuss-new-nrx-101-pipeline-indication-for-augmentation-of-transcranial-magnetic-stimulation/",
      "time_published": "20251204T044232",
      "authors": [
        "Investing News Network"
      ],
      "summary": "NRx Pharmaceuticals has amended its Investigational New Drug filing for NRX-101 to include its use in conjunction with Transcranial Magnetic Stimulation (TMS) for depression. This decision follows promising clinical data indicating that D-cycloserine, a component of NRX-101, significantly augments the antidepressant and antisuicidal effects of TMS. The company plans to collaborate with TMS device manufacturers on clinical trials, aiming for drug registration and enhanced FDA labeling, anticipating a substantial new market for NRX-101 by 2030.",
      "banner_image": "https://investingnews.com/media-library/image.gif?id=29654767&width=1200&height=1200",
      "source": "Investing News Network",
      "category_within_source": "General",
      "source_domain": "Investing News Network",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.943902"
        },
        {
          "topic": "finance",
          "relevance_score": "0.605813"
        }
      ],
      "overall_sentiment_score": 0.472383,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "NRXP",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.465191",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "NRx Pharmaceuticals to discuss new NRX-101 pipeline indication for augmentation of Transcranial Magnetic Stimulation",
      "url": "https://finance.yahoo.com/news/nrx-pharmaceuticals-discuss-nrx-101-120000053.html",
      "time_published": "20251203T140859",
      "authors": [
        "NULL"
      ],
      "summary": "NRx Pharmaceuticals has amended its Investigational New Drug (IND) filing for NRX-101 (D-cycloserine/lurasidone) to include its use with Transcranial Magnetic Stimulation (TMS) for depression, including suicidal depression. The company believes NRX-101 can significantly augment TMS results, citing studies showing improved clinical response and remission rates when D-cycloserine is combined with TMS. NRx Pharmaceuticals aims to partner with TMS device manufacturers for clinical trials to achieve drug registration and expanded FDA labeling.",
      "banner_image": "https://s.yimg.com/ny/api/res/1.2/rj0Ta3GGeVAy26gXI.Thag--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIyNDtoPTQ4O2NmPXdlYnA-/https://s.yimg.com/os/creatr-uploaded-images/2025-08/b2b7bbc0-8385-11f0-977e-d9d7d4cd04d2",
      "source": "Yahoo Finance",
      "category_within_source": "General",
      "source_domain": "Yahoo Finance",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "1.000000"
        }
      ],
      "overall_sentiment_score": 0.494677,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "NRXP",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.453189",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "NRx Pharmaceuticals Announces US Food and Drug Administration Receipt of ANDA for KETAFREE, a Preservative-Free IV Ketamine",
      "url": "https://investingnews.com/nrx-pharmaceuticals-announces-us-food-and-drug-administration-receipt-of-anda-for-ketafree-a-preservative-free-iv-ketamine/",
      "time_published": "20251202T160912",
      "authors": [
        "Investing News Network"
      ],
      "summary": "NRx Pharmaceuticals announced that the FDA has received its Abbreviated New Drug Application (ANDA) for KETAFREE\u2122, a preservative-free intravenous ketamine formulation. The FDA deemed the application \"substantially complete\" and set a goal date of July 29, 2026, for potential marketing approval. KETAFREE\u2122 aims to address the issue of potentially toxic preservatives in current multi-dose ketamine products and is intended for all currently approved ketamine indications.",
      "banner_image": "https://investingnews.com/media-library/image.gif?id=29654767&width=1200&height=1200",
      "source": "Investing News Network",
      "category_within_source": "General",
      "source_domain": "Investing News Network",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "1.000000"
        }
      ],
      "overall_sentiment_score": 0.49104,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "NRXP",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.483727",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "NRx Pharmaceuticals (NRXP) Announces FDA Receipt of ANDA for KETAFREE With July 2026 Review Goal Date",
      "url": "https://finance.yahoo.com/news/nrx-pharmaceuticals-nrxp-announces-fda-193000592.html",
      "time_published": "20251202T113000",
      "authors": [
        "NULL"
      ],
      "summary": "NRx Pharmaceuticals announced that the FDA has received its Abbreviated New Drug Application (ANDA) for KETAFREE, a preservative-free intravenous ketamine formulation, and deemed it \"substantially complete.\" The FDA has assigned a review goal date of July 29, 2026. KETAFREE aims to offer a single-patient, preservative-free alternative to current multidose ketamine vials containing Benzethonium Chloride, a compound no longer recognized as safe by the FDA.",
      "banner_image": "https://s.yimg.com/ny/api/res/1.2/LqOQbz3pbMh6KpfAeZPzSg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTM2MjtoPTQ4O2NmPXdlYnA-/https://s.yimg.com/os/creatr-uploaded-images/2021-12/6f6ffec0-56db-11ec-bddf-e7625a5e302f",
      "source": "Yahoo Finance",
      "category_within_source": "General",
      "source_domain": "Yahoo Finance",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.912478"
        }
      ],
      "overall_sentiment_score": 0.416764,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "NRXP",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.401230",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "NRx Pharmaceuticals (NASDAQ: NRXP) and HOPE Therapeutics to Host Corporate Update Call",
      "url": "https://www.globenewswire.com/news-release/2025/12/02/3197792/0/en/nrx-pharmaceuticals-nasdaq-nrxp-and-hope-therapeutics-to-host-corporate-update-call.html",
      "time_published": "20251202T073000",
      "authors": [
        "NULL"
      ],
      "summary": "NRx Pharmaceuticals and HOPE Therapeutics announced they will host a corporate update conference call on Tuesday, December 2, 2025, at 9:00 AM ET. The call will cover recent clinical, regulatory, and operational developments. A live webcast will be available on the Company's website.",
      "banner_image": "https://ml.globenewswire.com/media/NGI2NTg0ZTMtODU5Yi00OGZhLWE1NDgtNjZlN2QyZDNkMzBlLTEwOTU2OTMtMjAyNS0xMi0wMi1lbg==/tiny/NRx-Pharmaceuticals-Inc.png",
      "source": "GlobeNewswire",
      "category_within_source": "General",
      "source_domain": "GlobeNewswire",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.917781"
        },
        {
          "topic": "earnings",
          "relevance_score": "0.833030"
        }
      ],
      "overall_sentiment_score": 0.252892,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "NRXP",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.274656",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "NRx Pharmaceuticals (NASDAQ:NRXP) and HOPE Therapeutics to Present at NobleCon21 - Noble Capital Markets\u2019 Twenty First Annual Emerging Growth Equity Conference",
      "url": "https://www.globenewswire.com/news-release/2025/12/01/3196980/0/en/NRx-Pharmaceuticals-NASDAQ-NRXP-and-HOPE-Therapeutics-to-Present-at-NobleCon21-Noble-Capital-Markets-Twenty-First-Annual-Emerging-Growth-Equity-Conference.html",
      "time_published": "20251202T044232",
      "authors": [
        "NULL"
      ],
      "summary": "NRx Pharmaceuticals and HOPE Therapeutics announced that Dr. Jonathan Javitt will present at NobleCon21 on December 3rd, 2025. The presentation will update investors on the company's expanded focus, including progress in investigational drugs, medical devices, and interventional psychiatric therapies for suicidal depression, PTSD, and related conditions. The company has begun generating clinical revenue and made significant drug development progress since its last appearance at NobleCon 2024.",
      "banner_image": "https://ml.globenewswire.com/media/M2FhNDQxMjctYjIxMC00OTg0LWE0NzktYzNhNjZmMDFhZjU2LTEwOTU2OTMtMjAyNS0xMi0wMS1lbg==/tiny/NRx-Pharmaceuticals-Inc.png",
      "source": "GlobeNewswire",
      "category_within_source": "General",
      "source_domain": "GlobeNewswire",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "1.000000"
        }
      ],
      "overall_sentiment_score": 0.468166,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "NRXP",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.456208",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "NRx Pharmaceuticals (NASDAQ: NRXP) and HOPE Therapeutics to Host Corporate Update Call",
      "url": "https://finance.yahoo.com/news/nrx-pharmaceuticals-nasdaq-nrxp-hope-123000533.html",
      "time_published": "20251201T140925",
      "authors": [
        "NULL"
      ],
      "summary": "NRx Pharmaceuticals and HOPE Therapeutics announced they will host a corporate update conference call on Tuesday, December 2, 2025, at 9:00 AM ET. The call will cover recent clinical, regulatory, and operational developments. A live webcast will be available on the company's website, with telephone access also provided.",
      "banner_image": "NULL",
      "source": "Yahoo Finance",
      "category_within_source": "General",
      "source_domain": "Yahoo Finance",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.914242"
        },
        {
          "topic": "earnings",
          "relevance_score": "0.849844"
        },
        {
          "topic": "finance",
          "relevance_score": "0.644331"
        }
      ],
      "overall_sentiment_score": 0.18496,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "NRXP",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.189411",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "NRx Pharmaceuticals (NASDAQ: NRXP) plans Dec. 2, 9:00am ET corporate update call",
      "url": "https://www.stocktitan.net/news/NRXP/n-rx-pharmaceuticals-nasdaq-nrxp-and-hope-therapeutics-to-host-xk32y4fk282p.html",
      "time_published": "20251130T140911",
      "authors": [
        "NULL"
      ],
      "summary": "NRx Pharmaceuticals (NASDAQ: NRXP) will host a corporate update call on December 2, 2025, at 9:00 AM ET, covering recent clinical, regulatory, and operational developments. A live webcast and dial-in options will be available for participants. The firm's stock experienced a negative market reaction following this routine announcement, consistent with some past events where neutral or positive news coincided with selling, possibly due to concerns over capital raising and potential dilution.",
      "banner_image": "NULL",
      "source": "Stock Titan",
      "category_within_source": "General",
      "source_domain": "Stock Titan",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.923257"
        },
        {
          "topic": "financial_markets",
          "relevance_score": "0.637878"
        }
      ],
      "overall_sentiment_score": 0.011818,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "NRXP",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.032443",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "NRx Pharmaceuticals, Inc. Reports Third Quarter 2025 Financial Results and Provides Corporate Update",
      "url": "https://investingnews.com/nrx-pharmaceuticals-inc-reports-third-quarter-2025-financial-results-and-provides-corporate-update/",
      "time_published": "20251117T160922",
      "authors": [
        "NULL"
      ],
      "summary": "NRx Pharmaceuticals, Inc. announced its Q3 2025 financial results and provided a corporate update, highlighting the re-filing of its Abbreviated New Drug Application for KETAFREE\u2122 with an expected Q2 2026 GDUFA date. The company also detailed the progress of HOPE Therapeutics' revenue-generating facilities and secured operating capital through July 2026. Additionally, NRx received FDA Fast Track Designation for NRX-100 and presented new Real-World Data supporting NRX-101's effectiveness in augmenting Transcranial Magnetic Stimulation.",
      "banner_image": "https://investingnews.com/media-library/image.gif?id=29654767&width=1200&height=1200",
      "source": "Investing News Network",
      "category_within_source": "General",
      "source_domain": "Investing News Network",
      "topics": [
        {
          "topic": "earnings",
          "relevance_score": "0.904458"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "1.000000"
        }
      ],
      "overall_sentiment_score": 0.388547,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "NRXP",
          "relevance_score": "0.986587",
          "ticker_sentiment_score": "0.646072",
          "ticker_sentiment_label": "Bullish"
        },
        {
          "ticker": "JNJ",
          "relevance_score": "0.574331",
          "ticker_sentiment_score": "0.101831",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Reports Third Quarter 2025 Financial Results and Provides Corporate Update",
      "url": "https://www.globenewswire.com/news-release/2025/11/17/3189115/0/en/NRx-Pharmaceuticals-Inc-NASDAQ-NRXP-Reports-Third-Quarter-2025-Financial-Results-and-Provides-Corporate-Update.html",
      "time_published": "20251117T080300",
      "authors": [
        "NULL"
      ],
      "summary": "NRx Pharmaceuticals, Inc. provided a corporate update and announced financial results for Q3 2025, reporting a loss from operations of $4.0 million. The company has advanced its NRX-100 and NRX-101 programs, including re-filing an ANDA for KETAFREE\u2122 and expanding access programs for NRX-101. Additionally, its subsidiary HOPE Therapeutics has initiated revenue generation and is expanding its network of interventional psychiatry clinics.",
      "banner_image": "https://ml.globenewswire.com/media/MmYzZjg3YWEtY2RmNy00MjU3LWExNzMtNmMxOWQ1MWI3YmYwLTEwOTU2OTMtMjAyNS0xMS0xNy1lbg==/tiny/NRx-Pharmaceuticals-Inc.png",
      "source": "GlobeNewswire",
      "category_within_source": "General",
      "source_domain": "GlobeNewswire",
      "topics": [
        {
          "topic": "earnings",
          "relevance_score": "0.907544"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "1.000000"
        },
        {
          "topic": "finance",
          "relevance_score": "0.746843"
        }
      ],
      "overall_sentiment_score": 0.441129,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "NRXP",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.422727",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "NRx Pharmaceuticals (NRXP) to Report Q3 2025 Financial Results and Host Conference Call on Nov. 17",
      "url": "https://finance.yahoo.com/news/nrx-pharmaceuticals-nrxp-report-q3-204223286.html",
      "time_published": "20251117T044232",
      "authors": [
        "NULL"
      ],
      "summary": "NRx Pharmaceuticals (NASDAQ: NRXP), a clinical-stage biopharmaceutical company, announced it will release its third quarter 2025 financial results before market open on Monday, November 17, 2025. This will be followed by a conference call at 8:30 a.m. ET to discuss corporate, financial, and operational updates. The company is developing therapeutics for central nervous system disorders, including suicidal depression, chronic pain, and PTSD.",
      "banner_image": "https://s.yimg.com/ny/api/res/1.2/LqOQbz3pbMh6KpfAeZPzSg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTM2MjtoPTQ4O2NmPXdlYnA-/https://s.yimg.com/os/creatr-uploaded-images/2021-12/6f6ffec0-56db-11ec-bddf-e7625a5e302f",
      "source": "Yahoo Finance",
      "category_within_source": "General",
      "source_domain": "Yahoo Finance",
      "topics": [
        {
          "topic": "earnings",
          "relevance_score": "0.943406"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.809159"
        }
      ],
      "overall_sentiment_score": 0.103551,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "NRXP",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.131205",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) to Report Third Quarter 2025 Financial Results on November 17, 2025",
      "url": "https://www.globenewswire.com/news-release/2025/11/12/3186285/0/en/NRx-Pharmaceuticals-Inc-NASDAQ-NRXP-to-Report-Third-Quarter-2025-Financial-Results-on-November-17-2025.html",
      "time_published": "20251112T083100",
      "authors": [
        "NULL"
      ],
      "summary": "NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) announced it will release its third quarter 2025 financial results on Monday, November 17, 2025, before the market opens. The company will also host a conference call at 8:30 AM ET the same day to provide a corporate and financial update, as well as discuss future operational plans. A live webcast and telephone access details are provided for those interested in joining.",
      "banner_image": "https://ml.globenewswire.com/media/NzRhMjYwOWYtNzFiNS00ZmI3LWFkZmUtZjFiNzg3ZTU2NWIzLTEwOTU2OTMtMjAyNS0xMS0xMi1lbg==/tiny/NRx-Pharmaceuticals-Inc.png",
      "source": "GlobeNewswire",
      "category_within_source": "General",
      "source_domain": "GlobeNewswire",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.910541"
        },
        {
          "topic": "earnings",
          "relevance_score": "0.921287"
        }
      ],
      "overall_sentiment_score": 0.135171,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "NRXP",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.145361",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "HOPE Therapeutics, Inc., an NRx Pharmaceuticals Subsidiary, Announces First-in-Florida Initiation of One Day (ONE-D) Depression Treatment in Partnership with Ampa Health",
      "url": "https://www.globenewswire.com/news-release/2025/11/10/3184538/0/en/HOPE-Therapeutics-Inc-an-NRx-Pharmaceuticals-Subsidiary-Announces-First-in-Florida-Initiation-of-One-Day-ONE-D-Depression-Treatment-in-Partnership-with-Ampa-Health.html",
      "time_published": "20251110T080300",
      "authors": [
        "NULL"
      ],
      "summary": "HOPE Therapeutics, Inc., a subsidiary of NRx Pharmaceuticals, has initiated the One Day (ONE-D) depression treatment protocol in Florida, partnering with Ampa Health. This protocol, utilizing an FDA-cleared device in combination with physician-presprescribed D-cycloserine and lisdexamfetamine, aims to achieve remission from treatment-resistant depression in a single day. HOPE Therapeutics is the first to deploy this Ampa technology in Florida, with plans for six locations by year-end 2025.",
      "banner_image": "https://ml.globenewswire.com/media/NWNmOGNmNGYtNzEyMC00NGZhLWI0YWUtMWZhZjg5Njg3NjM1LTEwOTU2OTMtMjAyNS0xMS0xMC1lbg==/tiny/NRx-Pharmaceuticals-Inc.png",
      "source": "GlobeNewswire",
      "category_within_source": "General",
      "source_domain": "GlobeNewswire",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.923149"
        }
      ],
      "overall_sentiment_score": 0.413294,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "NRXP",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.404541",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "HOPE Therapeutics, Inc. and NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Announce Inclusion of Cohen & Associates, LLC of Sarasota, FL into the HOPE Network and Appointment of Dr. Rebecca Cohen as HOPE Medical Director",
      "url": "https://www.globenewswire.com/news-release/2025/10/20/3169337/0/en/HOPE-Therapeutics-Inc-and-NRx-Pharmaceuticals-Inc-NASDAQ-NRXP-Announce-Inclusion-of-Cohen-Associates-LLC-of-Sarasota-FL-into-the-HOPE-Network-and-Appointment-of-Dr-Rebecca-Cohen-as.html",
      "time_published": "20251020T080300",
      "authors": [],
      "summary": "HOPE Therapeutics, Inc., a subsidiary of NRx Pharmaceuticals, Inc., has announced the acquisition of a strategic interest in Cohen & Associates, LLC, incorporating it into the HOPE Network. Concurrently, Dr. Rebecca Cohen, founder of Cohen & Associates, LLC, has been appointed as HOPE Medical Director, overseeing medical standards across Florida locations. This expansion aims to leverage Dr. Cohen's expertise in interventional psychiatry and TMS to address suicidal depression and other CNS disorders, with further growth planned for Western Florida and Palm Beach.",
      "banner_image": "https://ml.globenewswire.com/media/ODU0NWYwOTUtZThkYS00MzE5LTkyYmItM2U0MzkxYjI0NjIxLTEwOTU2OTMtMjAyNS0xMC0yMC1lbg==/tiny/NRx-Pharmaceuticals-Inc.png",
      "source": "GlobeNewswire",
      "category_within_source": "General",
      "source_domain": "GlobeNewswire",
      "topics": [
        {
          "topic": "mergers_and_acquisitions",
          "relevance_score": "1.000000"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "1.000000"
        }
      ],
      "overall_sentiment_score": 0.481376,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "NRXP",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.488580",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Given Consensus Rating of \u201cModerate Buy\u201d by Analysts - Defense World",
      "url": "https://www.defenseworld.net/2025/10/19/nrx-pharmaceuticals-inc-nasdaqnrxp-given-consensus-rating-of-moderate-buy-by-analysts.html",
      "time_published": "20251019T063918",
      "authors": [
        "Defense World Staff"
      ],
      "summary": "Several brokerage firms have issued \"buy\" ratings and price objectives for NRx Pharmaceuticals (NASDAQ:NRXP) shares, indicating a consensus \"Moderate Buy\" rating. The stock recently traded up 4.6% to $1.36 and closed at $0.09. Anson Funds Management LP significantly increased its holdings in NRXP, reflecting growing institutional investor interest.",
      "banner_image": "https://www.marketbeat.com/logos/nrx-pharmaceuticals-inc-logo-1200x675.png",
      "source": "Defense World",
      "category_within_source": "General",
      "source_domain": "Defense World",
      "topics": [
        {
          "topic": "earnings",
          "relevance_score": "0.925157"
        },
        {
          "topic": "financial_markets",
          "relevance_score": "0.841218"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.924327"
        }
      ],
      "overall_sentiment_score": 0.005262,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "NRXP",
          "relevance_score": "0.302059",
          "ticker_sentiment_score": "0.024365",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "NRx Pharmaceuticals\u2019 (NRXP) Buy Rating Reiterated at HC Wainwright - Defense World",
      "url": "https://www.defenseworld.net/2025/10/19/nrx-pharmaceuticals-nrxp-buy-rating-reiterated-at-hc-wainwright.html",
      "time_published": "20251019T060540",
      "authors": [
        "Defense World Staff"
      ],
      "summary": "HC Wainwright has reiterated a \"buy\" rating for NRx Pharmaceuticals (NRXP), following similar endorsements from D. Boral Capital and BTIG Research. The company's stock rose by 4.6%, and institutional investor Geode Capital Management LLC increased its stake. NRx Pharmaceuticals is a clinical-stage biopharmaceutical company focused on central nervous system disorders with assets like NRX-101 and NRX-100.",
      "banner_image": null,
      "source": "Defense World",
      "category_within_source": "General",
      "source_domain": "Defense World",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.943124"
        },
        {
          "topic": "financial_markets",
          "relevance_score": "0.843541"
        }
      ],
      "overall_sentiment_score": 0.025951,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "NRXP",
          "relevance_score": "0.323553",
          "ticker_sentiment_score": "0.012195",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "NRx Pharmaceuticals (NASDAQ:NRXP) Shares Down 4.1% \u2013 Here\u2019s Why",
      "url": "https://www.defenseworld.net/2025/10/17/nrx-pharmaceuticals-nasdaqnrxp-shares-down-4-1-heres-why.html",
      "time_published": "20251017T192200",
      "authors": [
        "Defense World Staff"
      ],
      "summary": "NRx Pharmaceuticals (NASDAQ:NRXP) shares were down 4.1% on October 17th, 2025. This article details recent analyst ratings, stock performance metrics like market capitalization and moving averages, and institutional investment activity including Anson Funds Management LP boosting its stake. The company profile highlights its focus on developing therapeutics for central nervous system disorders.",
      "banner_image": "https://www.marketbeat.com/logos/nrx-pharmaceuticals-inc-logo-1200x675.png",
      "source": "Defense World",
      "category_within_source": "General",
      "source_domain": "Defense World",
      "topics": [
        {
          "topic": "earnings",
          "relevance_score": "0.925081"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.800334"
        },
        {
          "topic": "financial_markets",
          "relevance_score": "0.836551"
        },
        {
          "topic": "finance",
          "relevance_score": "0.629924"
        }
      ],
      "overall_sentiment_score": 0.010916,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "NRXP",
          "relevance_score": "0.337482",
          "ticker_sentiment_score": "0.014097",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "NRx Pharmaceuticals (NRXP) Pursues Dual Pathway for Preservative-Free Ketamine-Based Therapies - Yahoo Finance",
      "url": "https://finance.yahoo.com/news/nrx-pharmaceuticals-nrxp-pursues-dual-190000916.html",
      "time_published": "20251017T190000",
      "authors": [
        "NewMediaWire"
      ],
      "summary": "NRx Pharmaceuticals (NRXP) is pursuing a dual pathway for its preservative-free ketamine-based therapies. The company refiled its Abbreviated New Drug Application (ANDA) for KETAFREE(TM) after FDA approval to remove a neurotoxic preservative, and is also advancing NRX-100 under a New Drug Application (NDA) for suicidal ideation in depression. Additionally, NRx Pharmaceuticals continues work on NRX-101 for suicidal bipolar depression, which holds Breakthrough Therapy designation.",
      "banner_image": null,
      "source": "Yahoo Finance",
      "category_within_source": "General",
      "source_domain": "Yahoo Finance",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "1.000000"
        }
      ],
      "overall_sentiment_score": 0.027678,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "NRXP",
          "relevance_score": "0.348316",
          "ticker_sentiment_score": "0.044009",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "NRx Pharmaceuticals (NASDAQ: NRXP) Pursues Dual Pathway for Preservative-Free Ketamine-Based Therapies",
      "url": "https://www.theglobeandmail.com/investing/markets/stocks/NRXP-Q/pressreleases/35529007/nrx-pharmaceuticals-nasdaq-nrxp-pursues-dual-pathway-for-preservative-free-ketamine-based-therapies/",
      "time_published": "20251017T145500",
      "authors": [
        "Investor Brand Network"
      ],
      "summary": "NRx Pharmaceuticals has refiled its Abbreviated New Drug Application (ANDA) for KETAFREE(TM), a preservative-free IV ketamine formulation, following FDA approval to remove benzethonium chloride. Concurrently, NRx is developing NRX-100, another preservative-free ketamine formulation for suicidal ideation, and continues work on NRX-101 for suicidal bipolar depression. These efforts demonstrate NRx's dual strategy in advancing preservative-free ketamine-based therapies.",
      "banner_image": "https://barchart-news-media-prod.aws.barchart.com/FC/ff1fd056e4da440aa8df76ff9f314bae/nrxp.png",
      "source": "The Globe and Mail",
      "category_within_source": "General",
      "source_domain": "The Globe and Mail",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "1.000000"
        }
      ],
      "overall_sentiment_score": 0.041083,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "NRXP",
          "relevance_score": "0.315703",
          "ticker_sentiment_score": "0.005948",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "H.C. Wainwright reiterates Buy rating on NRx Pharmaceuticals stock at $40 - Investing.com Nigeria",
      "url": "https://ng.investing.com/news/analyst-ratings/hc-wainwright-reiterates-buy-rating-on-nrx-pharmaceuticals-stock-at-40-93CH-2149084",
      "time_published": "20251017T063038",
      "authors": [],
      "summary": "H.C. Wainwright has reiterated a Buy rating on NRx Pharmaceuticals stock, maintaining a $40 price target. The article, however, experienced a client-side exception when loading, indicating a potential technical issue preventing full content display.",
      "banner_image": null,
      "source": "Investing.com Nigeria",
      "category_within_source": "General",
      "source_domain": "Investing.com Nigeria",
      "topics": [
        {
          "topic": "earnings",
          "relevance_score": "0.920100"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.725925"
        },
        {
          "topic": "finance",
          "relevance_score": "0.535733"
        },
        {
          "topic": "financial_markets",
          "relevance_score": "0.427047"
        }
      ],
      "overall_sentiment_score": 0.018427,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "NRXP",
          "relevance_score": "0.319427",
          "ticker_sentiment_score": "0.025897",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "H.C. Wainwright reiterates Buy rating on NRx Pharmaceuticals stock at $40 By Investing.com - Investing.com Australia",
      "url": "https://m.au.investing.com/news/analyst-ratings/hc-wainwright-reiterates-buy-rating-on-nrx-pharmaceuticals-stock-at-40-93CH-4064977?ampMode=1",
      "time_published": "20251016T192815",
      "authors": [
        "Investing.com"
      ],
      "summary": "H.C. Wainwright has reiterated its Buy rating and $40 price target on NRx Pharmaceuticals (NASDAQ:NRXP) following a recent FDA approval for a competitor's drug, which is seen as a positive indicator for NRx's regulatory prospects. The firm noted the FDA's pragmatic approach to neuropsychiatric drug reviews supports confidence in NRX-101\u2019s accelerated-approval pathway. NRx Pharmaceuticals also has multiple near-term catalysts including the completion of an NDA for NRX-100 and ongoing regulatory progress for NRX-101.",
      "banner_image": "https://i-invdn-com.investing.com/news/international_newspapers_108x81.jpg",
      "source": "Investing.com Australia",
      "category_within_source": "General",
      "source_domain": "Investing.com Australia",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.929119"
        },
        {
          "topic": "earnings",
          "relevance_score": "0.742604"
        },
        {
          "topic": "financial_markets",
          "relevance_score": "0.601907"
        }
      ],
      "overall_sentiment_score": 0.043326,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "NRXP",
          "relevance_score": "0.301987",
          "ticker_sentiment_score": "0.006770",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "H.C. Wainwright reiterates Buy rating on NRx Pharmaceuticals stock at $40 - Investing.com",
      "url": "https://www.investing.com/news/analyst-ratings/hc-wainwright-reiterates-buy-rating-on-nrx-pharmaceuticals-stock-at-40-93CH-4291954",
      "time_published": "20251016T121116",
      "authors": [],
      "summary": "This article reports that H.C. Wainwright has reiterated its Buy rating on NRx Pharmaceuticals stock, maintaining a $40 price target. However, the article content is completely unavailable due to what appears to be a client-side application error on the Investing.com website.",
      "banner_image": null,
      "source": "Investing.com",
      "category_within_source": "General",
      "source_domain": "Investing.com",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.910756"
        }
      ],
      "overall_sentiment_score": 0.037309,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "NRXP",
          "relevance_score": "0.320203",
          "ticker_sentiment_score": "0.021024",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "H.C. Wainwright reiterates Buy rating on NRx Pharmaceuticals stock at $40 - Investing.com",
      "url": "https://m.investing.com/news/analyst-ratings/hc-wainwright-reiterates-buy-rating-on-nrx-pharmaceuticals-stock-at-40-93CH-4291954?ampMode=1",
      "time_published": "20251016T112800",
      "authors": [
        "Investing.com"
      ],
      "summary": "H.C. Wainwright has reiterated its Buy rating and $40 price target on NRx Pharmaceuticals (NRXP) following a competitor's FDA approval, which is seen as a positive indicator for NRx's regulatory prospects. The firm highlights NRXP's 158% return over the past year and points to several near-term catalysts including NDA completion for NRX-100 and ongoing regulatory progress for NRX-101. The article also mentions NRx's recent re-filing of an Abbreviated New Drug Application for KETAFREE and expansion of its mental health services.",
      "banner_image": "https://i-invdn-com.investing.com/news/international_newspapers_108x81.jpg",
      "source": "Investing.com",
      "category_within_source": "General",
      "source_domain": "Investing.com",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.908967"
        },
        {
          "topic": "earnings",
          "relevance_score": "0.706356"
        },
        {
          "topic": "financial_markets",
          "relevance_score": "0.644785"
        }
      ],
      "overall_sentiment_score": 0.046779,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "NRXP",
          "relevance_score": "0.318030",
          "ticker_sentiment_score": "0.030632",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "New to The Street Broadcasts Tonight on Bloomberg Featuring Roadzen, Metaterra, NRx Pharma, Blackbarn NYC, and Humanitarian Travel Group - Asbury Park Press",
      "url": "https://www.app.com/press-release/story/9966/new-to-the-street-broadcasts-tonight-on-bloomberg-featuring-roadzen-metaterra-nrx-pharma-blackbarn-nyc-and-humanitarian-travel-group/",
      "time_published": "20251011T193955",
      "authors": [
        "new to the street"
      ],
      "summary": "New to The Street will broadcast tonight on Bloomberg Television at 6:30 PM EST, featuring interviews with several companies and organizations. The program will highlight Roadzen Inc. (NASDAQ:RDZN), Metaterra Holdings, NRx Pharmaceuticals (NASDAQ:NRXP), Blackbarn NYC, and Melanie Soloway of Humanitarian Travel Group. The show, sponsored programming, also includes commercials for LASE Technologies ($LASE), PetVivo ($PETV), Acurx Pharmaceuticals ($ACXP), Synergy CHC ($SNYR), and NewsOut.",
      "banner_image": "https://app.accessnewswire.com/imagelibrary/a002b6f2-b74b-467b-bf3a-7b4892729294/1085810/bloombergjane.jpg",
      "source": "Asbury Park Press",
      "category_within_source": "General",
      "source_domain": "Asbury Park Press",
      "topics": [
        {
          "topic": "finance",
          "relevance_score": "0.809258"
        },
        {
          "topic": "technology",
          "relevance_score": "0.732703"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.630584"
        }
      ],
      "overall_sentiment_score": 0.024223,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "NRXP",
          "relevance_score": "0.328926",
          "ticker_sentiment_score": "0.000306",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "NRx Pharmaceuticals (NRXP) Strengthens Pipeline With Dual Pathways for Ketamine-Based Therapies",
      "url": "https://finance.yahoo.com/news/nrx-pharmaceuticals-nrxp-strengthens-pipeline-183612539.html",
      "time_published": "20251009T150935",
      "authors": [
        "NULL"
      ],
      "summary": "NRx Pharmaceuticals (NRXP) is advancing its ketamine-based therapy pipeline through dual pathways. The company has refiled an Abbreviated New Drug Application (ANDA) for KETAFREE\u2122, a preservative-free IV ketamine formulation, and is also developing NRX-100, another preservative-free ketamine formulation under a New Drug Application (NDA) for suicidal depression. Additionally, NRx is working on NRX-101, an oral medication for suicidal bipolar depression with Breakthrough Therapy Designation, aiming to address critical needs in mental health and drug shortages.",
      "banner_image": "NULL",
      "source": "Yahoo Finance",
      "category_within_source": "General",
      "source_domain": "Yahoo Finance",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "1.000000"
        }
      ],
      "overall_sentiment_score": 0.000358,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "NRXP",
          "relevance_score": "0.318066",
          "ticker_sentiment_score": "0.003537",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "HOPE Therapeutics, Inc. and NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Announce Receipt of Final Clearance to Proceed to Closing of Dura Medical Acquisition from Florida's Agency for Health Care Administration (AHCA)",
      "url": "https://www.prnewswire.com/news-releases/hope-therapeutics-inc-and-nrx-pharmaceuticals-inc-nasdaqnrxp-announce-receipt-of-final-clearance-to-proceed-to-closing-of-dura-medical-acquisition-from-floridas-agency-for-health-care-administration-ahca-302525049.html",
      "time_published": "20250808T080300",
      "authors": [
        "NULL"
      ],
      "summary": "HOPE Therapeutics, Inc., a subsidiary of NRx Pharmaceuticals, Inc., has received final clearance from the Florida Agency for Health Care Administration (AHCA) to close its acquisition of Dura Medical LLC. This acquisition, along with previous ones, aims to expand precision psychiatry services, including Ketamine therapy and TMS, for both veteran and civilian patients across West Coast Florida. The acquisition is expected to be accretive to both revenue and EBITDA.",
      "banner_image": "NULL",
      "source": "PR Newswire",
      "category_within_source": "General",
      "source_domain": "PR Newswire",
      "topics": [
        {
          "topic": "mergers_and_acquisitions",
          "relevance_score": "1.000000"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.935844"
        }
      ],
      "overall_sentiment_score": 0.403691,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "NRXP",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.447027",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Files Initial Section of U.S. New Drug Application to the FDA for NRX-100 (IV Ketamine) for the Treatment of Suicidal Depression",
      "url": "https://www.prnewswire.com/news-releases/nrx-pharmaceuticals-inc-nasdaqnrxp-files-initial-section-of-us-new-drug-application-to-the-fda-for-nrx-100-iv-ketamine-for-the-treatment-of-suicidal-depression-302340035.html",
      "time_published": "20241230T080300",
      "authors": [],
      "summary": "NRx Pharmaceuticals, Inc. has filed the initial section of its New Drug Application (NDA) with the FDA for NRX-100 (IV ketamine) for the treatment of suicidal depression, aiming to be the first FDA-approved medication for this condition. The company expects to complete the NDA filing in Q1 2025 and is seeking to expand the indication to include Suicidal Ideation in Major Depressive Disorder, building on data from NIH- and European Government-funded trials. This move addresses the urgent need for new treatment options for the millions of Americans who seriously consider suicide annually.",
      "banner_image": null,
      "source": "PR Newswire",
      "category_within_source": "General",
      "source_domain": "PR Newswire",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "1.000000"
        }
      ],
      "overall_sentiment_score": 0.485432,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "NRXP",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.470960",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Reschedules Conference Call to Discuss Third Quarter and Year to Date 2024 Financial Results to November 18, 2024",
      "url": "https://www.nasdaq.com/press-release/nrx-pharmaceuticals-inc-nasdaq-nrxp-reschedules-conference-call-discuss-third-quarter",
      "time_published": "20241113T080300",
      "authors": [],
      "summary": "NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) has rescheduled its third quarter and year-to-date 2024 financial results conference call to Monday, November 18, 2024, at 4:30 pm ET. This change was made to accommodate potential additional corporate news. The call will be accessible via webcast on the company's website and through telephone.",
      "banner_image": null,
      "source": "Nasdaq",
      "category_within_source": "General",
      "source_domain": "Nasdaq",
      "topics": [
        {
          "topic": "earnings",
          "relevance_score": "1.000000"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.923558"
        },
        {
          "topic": "finance",
          "relevance_score": "0.600831"
        }
      ],
      "overall_sentiment_score": 0.01985,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "NRXP",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.049093",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "NRx Pharmaceuticals Unveils Breakthrough Ketamine Formulation for Pain-Free Administration",
      "url": "https://www.mychesco.com/a/news/regional/nrx-pharmaceuticals-unveils-breakthrough-ketamine-formulation-for-pain-free-administration/",
      "time_published": "20240421T000000",
      "authors": [
        "Timothy Alexander"
      ],
      "summary": "NRx Pharmaceuticals, in collaboration with Nephron Pharmaceuticals, has developed HTX-100, a novel, pain-free IV Ketamine formulation with a neutral pH, addressing issues with existing acidic formulations. This innovation is patentable and could enable subcutaneous administration via insulin pump-like devices, simplifying treatment and monitoring for patients. The development represents a significant advancement in modernizing ketamine therapy for broader and more personalized medical use.",
      "banner_image": null,
      "source": "MyChesCo",
      "category_within_source": "General",
      "source_domain": "MyChesCo",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.901374"
        }
      ],
      "overall_sentiment_score": 0.024772,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "NRXP",
          "relevance_score": "0.300440",
          "ticker_sentiment_score": "0.018364",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "NRx Pharmaceuticals Announces Proposed Underwritten Public Offering of Common Stock",
      "url": "https://www.citybiz.co/article/544800/nrx-pharmaceuticals-announces-proposed-underwritten-public-offering-of-common-stock/",
      "time_published": "20240417T000000",
      "authors": [],
      "summary": "NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) announced its intention to offer and sell shares of its common stock in an underwritten public offering. The offering's terms, including size and completion, are subject to market conditions. EF Hutton LLC is serving as the sole book-running manager, and NRx Pharmaceuticals plans to use the net proceeds for working capital, general corporate purposes, and potentially to repay outstanding debt.",
      "banner_image": null,
      "source": "citybiz",
      "category_within_source": "General",
      "source_domain": "citybiz",
      "topics": [
        {
          "topic": "finance",
          "relevance_score": "0.911218"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.837344"
        }
      ],
      "overall_sentiment_score": -0.21751,
      "overall_sentiment_label": "Somewhat-Bearish",
      "ticker_sentiment": [
        {
          "ticker": "NRXP",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "-0.212585",
          "ticker_sentiment_label": "Somewhat-Bearish"
        }
      ]
    },
    {
      "title": "NRx Pharmaceuticals, Inc. Announces Pricing of $1.5 Million Underwritten Public Offering of Common Stock Together with investor Commitment for Additional $1 million",
      "url": "https://www.biospace.com/nrx-pharmaceuticals-inc-announces-pricing-of-1-5-million-underwritten-public-offering-of-common-stock-together-with-investor-commitment-for-additional-1-million",
      "time_published": "20240227T070000",
      "authors": [],
      "summary": "NRx Pharmaceuticals, Inc. announced the pricing of an underwritten public offering of common stock totaling $1.5 million at $0.30 per share. Concurrently, an existing investor committed an additional $1 million under the same terms. The company plans to use the net proceeds for working capital, general corporate purposes, and to service debt obligations, aiming to extend its financial runway and support upcoming clinical trial readouts and the launch of HOPE Therapeutics.",
      "banner_image": null,
      "source": "BioSpace",
      "category_within_source": "General",
      "source_domain": "BioSpace",
      "topics": [
        {
          "topic": "finance",
          "relevance_score": "0.927847"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.822627"
        }
      ],
      "overall_sentiment_score": 0.210998,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "NRXP",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.196515",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "Relief Therapeutics Holding SA and NRx Pharmaceuticals, Inc. Announce Close of Definitive Settlement Agreements",
      "url": "https://www.prnewswire.com/news-releases/relief-therapeutics-holding-sa-and-nrx-pharmaceuticals-inc-announce-close-of-definitive-settlement-agreements-301706901.html",
      "time_published": "20221220T013000",
      "authors": [],
      "summary": "Relief Therapeutics Holding SA and NRx Pharmaceuticals, Inc. have announced the close of definitive settlement agreements to resolve their pending litigation. Under the terms, NeuroRx, a subsidiary of NRx Pharmaceuticals, has transferred all aviptadil development assets to Relief, granting Relief exclusive rights and obligations for its development and commercialization. Relief will also pay NeuroRx milestone payments and royalties on future aviptadil sales, up to $30 million.",
      "banner_image": null,
      "source": "PR Newswire",
      "category_within_source": "General",
      "source_domain": "PR Newswire",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "1.000000"
        }
      ],
      "overall_sentiment_score": 0.151273,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "NRXP",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.276116",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "PFE",
          "relevance_score": "0.560211",
          "ticker_sentiment_score": "0.122605",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "MMM",
          "relevance_score": "0.561162",
          "ticker_sentiment_score": "0.147882",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "NRx Pharmaceuticals to Report Third Quarter 2022 Results on November 14, 2022 (2022-11-10)",
      "url": "https://seekingalpha.com/pr/19015277-nrx-pharmaceuticals-to-report-third-quarter-2022-results-on-november-14-2022",
      "time_published": "20221110T064700",
      "authors": [],
      "summary": "NRx Pharmaceuticals announced it will report its third-quarter 2022 financial results on November 14, 2022, prior to market open. The company will also host a conference call and webcast at 8:00 AM ET to discuss these results and provide clinical and corporate updates. Key areas of discussion will likely include updates on their lead product candidate, NRX-101, for severe bipolar depression with suicidal ideation, which has Breakthrough Therapy Designation from the FDA.",
      "banner_image": null,
      "source": "Seeking Alpha",
      "category_within_source": "General",
      "source_domain": "Seeking Alpha",
      "topics": [
        {
          "topic": "earnings",
          "relevance_score": "0.924625"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.826951"
        }
      ],
      "overall_sentiment_score": 0.134276,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "NRXP",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.145607",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "NRx Pharmaceuticals Produces First Phase 3-stage NRX-101 Drug Made Using Commercial Process",
      "url": "https://www.prnewswire.com/news-releases/nrx-pharmaceuticals-produces-first-phase-3-stage-nrx-101-drug-made-using-commercial-process-301672545.html",
      "time_published": "20221109T064700",
      "authors": [],
      "summary": "NRx Pharmaceuticals announced the release of the first batches of its Phase 3-ready investigational drug, NRX-101, manufactured in the U.S. using a commercial process. This strategic move aims to shorten the time to market availability for NRX-101, which targets suicidal bipolar depression and has received Breakthrough Therapy Designation from the FDA. The company is preparing to initiate a Phase 3 trial for bipolar depression in patients with acute suicidal ideation and behavior.",
      "banner_image": null,
      "source": "PR Newswire",
      "category_within_source": "General",
      "source_domain": "PR Newswire",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.913439"
        },
        {
          "topic": "manufacturing",
          "relevance_score": "0.706257"
        }
      ],
      "overall_sentiment_score": 0.411638,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "NRXP",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.446102",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "NRx Pharmaceuticals Appoints Stephen Willard as CEO",
      "url": "https://www.contractpharma.com/breaking-news/nrx-pharmaceuticals-appoints-stephen-willard-as-ceo/",
      "time_published": "20220713T175555",
      "authors": [
        "Charlie Sternberg"
      ],
      "summary": "NRx Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, has appointed Stephen Willard as its new chief executive officer and a member of its Board of Directors. Willard brings extensive experience in managing publicly traded biotechnology companies, previously serving as CEO of Cellphire Therapeutics and Flamel Technologies, now Avadel Pharmaceuticals. Interim CEO Robert Besthof will return to his roles as head of operations and chief commercial officer.",
      "banner_image": null,
      "source": "Contract Pharma",
      "category_within_source": "General",
      "source_domain": "Contract Pharma",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "1.000000"
        },
        {
          "topic": "finance",
          "relevance_score": "0.710739"
        }
      ],
      "overall_sentiment_score": 0.445104,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "NRXP",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.445977",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "NRx Pharmaceuticals Announces the Appointment of Stephen Willard, Chief Executive Officer and Director",
      "url": "https://www.prnewswire.com/news-releases/nrx-pharmaceuticals-announces-the-appointment-of-stephen-willard-chief-executive-officer-and-director-301585575.html",
      "time_published": "20220713T071500",
      "authors": [],
      "summary": "NRx Pharmaceuticals announced the appointment of Stephen Willard as its new Chief Executive Officer and a member of its Board of Directors. Willard brings extensive experience in law, finance, and biotechnology management, with previous CEO roles at Cellphire Therapeutics and Flamel Technologies. He is also a presidential appointee to the National Science Board and will focus on advancing NRX-101 for suicidal bipolar depression and the company's neuroscience pipeline.",
      "banner_image": null,
      "source": "PR Newswire",
      "category_within_source": "General",
      "source_domain": "PR Newswire",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.906113"
        },
        {
          "topic": "finance",
          "relevance_score": "0.723888"
        }
      ],
      "overall_sentiment_score": 0.497757,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "NRXP",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.493158",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "NRx Pharmaceuticals Announces First Successful Commercial Formulation for ZYESAMI\u2122 (aviptadil), Enabling Volume Manufacture, Shipping, and Stockpiling of COVID-19 Medication Subject to Regulatory Approval",
      "url": "https://www.prnewswire.com/news-releases/nrx-pharmaceuticals-announces-first-successful-commercial-formulation-for-zyesami-aviptadil-enabling-volume-manufacture-shipping-and-stockpiling-of-covid-19-medication-subject-to-regulatory-approval-301339154.html",
      "time_published": "20210722T064800",
      "authors": [],
      "summary": "NRx Pharmaceuticals announced the successful validation of a commercial formulation for ZYESAMI\u2122 (aviptadil), allowing for high-volume manufacturing, shipping, and stockpiling of the COVID-19 medication. This new formulation significantly increases the manufactured lot size by 30 to 50-fold and reduces peptide supply costs by 90%, enabling the potential delivery of millions of doses worldwide pending regulatory approvals. The new method also addresses stability issues and is designed to meet Good Manufacturing Practices (GMP) regulations.",
      "banner_image": null,
      "source": "PR Newswire",
      "category_within_source": "General",
      "source_domain": "PR Newswire",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.931333"
        },
        {
          "topic": "finance",
          "relevance_score": "0.626597"
        }
      ],
      "overall_sentiment_score": 0.408147,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "NRXP",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.410929",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    }
  ]
}